GB201901608D0 - Vaccine adjuvant conjugates - Google Patents

Vaccine adjuvant conjugates

Info

Publication number
GB201901608D0
GB201901608D0 GBGB1901608.8A GB201901608A GB201901608D0 GB 201901608 D0 GB201901608 D0 GB 201901608D0 GB 201901608 A GB201901608 A GB 201901608A GB 201901608 D0 GB201901608 D0 GB 201901608D0
Authority
GB
United Kingdom
Prior art keywords
vaccine adjuvant
adjuvant conjugates
conjugates
vaccine
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1901608.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB filed Critical Universiteit Gent
Priority to GBGB1901608.8A priority Critical patent/GB201901608D0/en
Publication of GB201901608D0 publication Critical patent/GB201901608D0/en
Ceased legal-status Critical Current

Links

GBGB1901608.8A 2019-02-06 2019-02-06 Vaccine adjuvant conjugates Ceased GB201901608D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB1901608.8A GB201901608D0 (en) 2019-02-06 2019-02-06 Vaccine adjuvant conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1901608.8A GB201901608D0 (en) 2019-02-06 2019-02-06 Vaccine adjuvant conjugates

Publications (1)

Publication Number Publication Date
GB201901608D0 true GB201901608D0 (en) 2019-03-27

Family

ID=65861490

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1901608.8A Ceased GB201901608D0 (en) 2019-02-06 2019-02-06 Vaccine adjuvant conjugates

Country Status (1)

Country Link
GB (1) GB201901608D0 (en)

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0549062A2 (en) 1991-12-23 1993-06-30 Gist-Brocades N.V. A eukaryotic expression system
WO1994000153A1 (en) 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
WO1995017210A1 (en) 1993-12-23 1995-06-29 Smithkline Beecham Biologicals (S.A.) Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1996033739A1 (en) 1995-04-25 1996-10-31 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
WO1999042077A2 (en) 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
WO2000009159A1 (en) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2002048187A2 (en) 2000-12-14 2002-06-20 Phylos, Inc. Secretion signal peptides, their dna sequences, expression vectors for eukaryotic cells that can be produced with the same, and use thereof for biotechnological production of proteins
US6573245B1 (en) 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006122825A2 (en) 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
WO2007095506A1 (en) 2006-02-10 2007-08-23 Invitrogen Corporation Oligosaccharide modification and labeling of proteins
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
WO2010015722A1 (en) 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof
WO2013036748A1 (en) 2011-09-09 2013-03-14 Berry, Lana, L. Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
WO2014065661A1 (en) 2012-10-23 2014-05-01 Synaffix B.V. Modified antibody, antibody-conjugate and process for the preparation thereof
WO2015032899A1 (en) 2013-09-05 2015-03-12 Vib Vzw Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof
WO2015057064A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
WO2015057063A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
WO2015057066A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015057065A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015112013A1 (en) 2014-01-24 2015-07-30 Synaffix B.V. Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
WO2016022027A1 (en) 2014-08-04 2016-02-11 Synaffix B.V. Process for the modification of a glycoprotein using a βeta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
WO2016053107A1 (en) 2014-10-03 2016-04-07 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
WO2016170186A1 (en) 2015-04-23 2016-10-27 Synaffix B.V. PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
WO2017005925A1 (en) 2015-07-09 2017-01-12 Vib Vzw Cells producing glycoproteins having altered n- and o-glycosylation patterns and methods and use thereof

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0549062A2 (en) 1991-12-23 1993-06-30 Gist-Brocades N.V. A eukaryotic expression system
WO1994000153A1 (en) 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
WO1995017210A1 (en) 1993-12-23 1995-06-29 Smithkline Beecham Biologicals (S.A.) Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1996033739A1 (en) 1995-04-25 1996-10-31 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
WO1999042077A2 (en) 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
US6573245B1 (en) 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
WO2000009159A1 (en) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2002048187A2 (en) 2000-12-14 2002-06-20 Phylos, Inc. Secretion signal peptides, their dna sequences, expression vectors for eukaryotic cells that can be produced with the same, and use thereof for biotechnological production of proteins
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006122825A2 (en) 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
WO2007095506A1 (en) 2006-02-10 2007-08-23 Invitrogen Corporation Oligosaccharide modification and labeling of proteins
WO2008029281A2 (en) 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
WO2010015722A1 (en) 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof
WO2013036748A1 (en) 2011-09-09 2013-03-14 Berry, Lana, L. Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
WO2014065661A1 (en) 2012-10-23 2014-05-01 Synaffix B.V. Modified antibody, antibody-conjugate and process for the preparation thereof
WO2015032899A1 (en) 2013-09-05 2015-03-12 Vib Vzw Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof
WO2015057063A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
WO2015057064A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
WO2015057066A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015057065A1 (en) 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015112013A1 (en) 2014-01-24 2015-07-30 Synaffix B.V. Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby
WO2016022027A1 (en) 2014-08-04 2016-02-11 Synaffix B.V. Process for the modification of a glycoprotein using a βeta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
WO2016053107A1 (en) 2014-10-03 2016-04-07 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
WO2016170186A1 (en) 2015-04-23 2016-10-27 Synaffix B.V. PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
WO2017005925A1 (en) 2015-07-09 2017-01-12 Vib Vzw Cells producing glycoproteins having altered n- and o-glycosylation patterns and methods and use thereof

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
ARNON R. ET AL., PROC. NATL. ACAD. SCI., vol. 77, no. 11, 1980, pages 6769
AUSUBEL ET AL.: "current Protocols in Molecular Biology (Supplement 100", 2012, JOHN WILEY & SONS
CAMPBELL, J.D., DEVELOPMENT OF THE CPG ADJUVANT 1018: A CASE STUDY, 2017, pages 15 - 27, Retrieved from the Internet <URL:https://doi.org/10.1007/978-l-4939-6445-l_2>
CHASIN ET AL., SOM. CELL MOLEC. GENET., vol. 12, 1986, pages 555 - 556
CHEN, B.J.; LESER, G.P.; MORITA, E.; LAMB, R.A.: "Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles", J. VIROL., vol. 81, 2007, pages 7111 - 23, XP055045415, Retrieved from the Internet <URL:https://doi.org/10.1128/JVI.00361-07> DOI: doi:10.1128/JVI.00361-07
CHEONG, W.-S.; REISEGER, J.; TURNER, S.J.; BOYD, R.; NETTER, H.-J.: "Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope", ANTIVIRAL RES., vol. 81, 2009, pages 113 - 122, XP025872395, Retrieved from the Internet <URL:https://doi. rg/10.1016/J.ANTIVIRAL.2008.10.003> DOI: doi:10.1016/j.antiviral.2008.10.003
DAVIS ET AL., J. AM. CHEM. SOC., vol. 134, 2012, pages 8030
GOLDBLATT D, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 119, no. 1, 2000, pages 1 - 3
GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59
HYAKUMURA, M.; WALSH, R.; THAYSEN-ANDERSEN, M.; KINGSTON, N.J.; LA, M.; LU, L.; LOVRECZ, G.; PACKER, N.H.; LOCARNINI, S.; NETTER,: "Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity", J. VIROL., vol. 89, 2015, pages 11312 - 22
KERVIEL, A.; DASH, S.; MONCORGE, O.; PANTHU, B.; PRCHAL, J.; DECIMO, D.; OHLMANN, T.; LINA, B.; FAVARD, C.; DECROLY, E.: "Involvement of an Arginine Triplet in M1 Matrix Protein Interaction with Membranes and in M1 Recruitment into Virus-Like Particles of the Influenza A(H1N1)pdm09 Virus", PLOS ONE, vol. 11, 2016, pages e0165421, Retrieved from the Internet <URL:https://doi.org/10.1371/journal.pone.0165421>
KLEE ET AL., BMC BIOINFORMATICS, vol. 6, 2005, pages 256
KOLKEKAR ET AL., BIOCHEMISTRY, vol. 36, 1997, pages 10901 - 10909
LAROY, W.; CONTRERAS, R.; CALLEWAERT, N.: "Glycome mapping on DNA sequencing equipment", NAT. PROTOC., vol. 1, 2006, pages 397 - 405, Retrieved from the Internet <URL:https://doi.org/10.1038/nprot.2006.60>
MATHER, ANNALS NYACAD. SCI., vol. 383, 1982, pages 44 - 68
MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251
MEIER, S.; GUTHE, S.; KIEFHABER, T.; GRZESIEK, S.: "Foldon, The Natural Trimerization Domain of T4 Fibritin, Dissociates into a Monomeric A-state Form containing a Stable β-Hairpin: Atomic Details of Trimer Dissociation and Local β-Hairpin Stability from Residual Dipolar Couplings", J. MOL. BIOL., vol. 344, 2004, pages 1051 - 1069, XP004635848, Retrieved from the Internet <URL:https://doi.org/10.1016/JJMB.2004.09.079> DOI: doi:10.1016/j.jmb.2004.09.079
PARK, A.; HONEY, D.M.; HOU, L.; BIRD, J.J.; ZARAZINSKI, C.; SEARLES, M.; BRAITHWAITE, C.; KINGSBURY, J.S.; KYAZIKE, J.; CULM-MERDE: "Carbohydrate-Mediated Polyethylene Glycol Conjugation of TSH Improves Its Pharmacological Properties", ENDOCRINOLOGY, vol. 154, 2013, pages 1373 - 1383, XP008160851, Retrieved from the Internet <URL:https://doi.org/10.1210/en.2012-2010> DOI: doi:10.1210/en.2012-2010
RANNES, J.B.; LOANNOU, A.; WILLIES, S.C.; GROGAN, G.; BEHRENS, C.; FLITSCH, S.L.; TURNER, N.J.: "Glycoprotein Labeling Using Engineered Variants of Galactose Oxidase Obtained by Directed Evolution", J. AM. CHEM. SOC., vol. 133, 2011, pages 8436 - 8439, Retrieved from the Internet <URL:https://doi.org/10.1021/ja2018477>
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR PRESS
SATO ET AL., SCIENCE, vol. 273, 1996, pages 352
SCHAAF ET AL., BMC BIOTECHNOL., vol. 5, 2005, pages 30
SHRIMAL, S.; GILMORE, R., J CELL SCI., vol. 126, no. 23, 2013
SHUKLA, N.M.; LEWIS, T.C.; DAY, T.P.; MUTZ, C.A.; UKANI, R.; HAMILTON, C.D.; BALAKRISHNA, R.; DAVID, S.A.: "Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines", BIOORG. MED. CHEM. LETT., vol. 21, 2011, pages 3232 - 6, XP028211454, Retrieved from the Internet <URL:https://doi.org/10.1016/j.bmcl.2011.04.050> DOI: doi:10.1016/j.bmcl.2011.04.050
SOLTYSIK, S.; WU, J.-Y.; RECCHIA, J.; WHEELER, D.A.; NEWMAN, M.J.; COUGHLIN, R.T.; KENSIL, C.R.: "Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function", VACCINE, vol. 13, 1995, pages 1403 - 1410, XP004057449, Retrieved from the Internet <URL:https://doi.org/10.1016/0264-410X(95)00077-E> DOI: doi:10.1016/0264-410X(95)00077-E
SUN, S.; ZHANG, H., ANAL. CHEM., vol. 87, no. 24, pages 2015
TAN ET AL., PROTEIN ENGINEERING, vol. 15, no. 4, 2002, pages 337 - 345
URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
VAN GEEL, R.; WIJDEVEN, M.A.; HEESBEEN, R.; VERKADE, J.M.M.; WASIEL, A.A.; VAN BERKEL, S.S.; VAN DELFT, F.L.: "Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates", BIOCONJUG. CHEM., vol. 26, 2015, pages 2233 - 2242, XP055249394, Retrieved from the Internet <URL:https://doi.org/10.1021/acs.bioconjchem.5b00224> DOI: doi:10.1021/acs.bioconjchem.5b00224
WANG, J. AM. CHEM. SOC., vol. 134, 2012, pages 12308
WU, Z.L.; HUANG, X.; BURTON, A.J.; SWIFT, K.A.D.: "Glycoprotein labeling with click chemistry (GLCC) and carbohydrate detection", CARBOHYDR. RES., vol. 412, 2015, pages 1 - 6, XP055448638, Retrieved from the Internet <URL:https://doi. rg/10.1016/J.CARRES.2015.04.018> DOI: doi:10.1016/j.carres.2015.04.018
YOUNIS, S.Y.; BARNIER-QUER, C.; HEUKING, S.; SOMMANDAS, V.; BRUNNER, L.; VD WERFF, N.; DUBOIS, P.; FRIEDE, M.; KOCKEN, C.; COLLIN,: "Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation", BMC IMMUNOL., vol. 19, 2018, pages 6, Retrieved from the Internet <URL:https://doi.org/10.1186/s12865-018-0245-0>
ZHU, D.; TUO, W.: "QS-21: A Potent Vaccine Adjuvant", NAT. PROD. CHEM. RES., 2015, pages 03, Retrieved from the Internet <URL:https://doi.org/10.4172/2329-6836.1000ell3>

Similar Documents

Publication Publication Date Title
GB202010425D0 (en) Combination vaccine
GB202002166D0 (en) Vaccine
IL292272A (en) Cancer vaccine
EP4213872A4 (en) Piv5-based covid-19 vaccine
GB201704417D0 (en) Improved li vaccine adjuvant
IL284249A (en) Preparation including vaccine adjuvant
GB201910794D0 (en) Vaccine
GB202016954D0 (en) Vaccine
GB2594637B (en) Novel trypanosomal vaccine
GB201901608D0 (en) Vaccine adjuvant conjugates
GB201811382D0 (en) Vaccine
GB201917699D0 (en) Vaccine conjugates
GB202001660D0 (en) Vaccine adjuvant conjugates
GB202119115D0 (en) Vaccine
GB202118110D0 (en) Vaccine
GB202114274D0 (en) SARS-CoV-2 vaccine
GB202112149D0 (en) Shigellla vaccine
GB202102677D0 (en) Vaccine
GB202016165D0 (en) Vaccine
GB202014719D0 (en) Vaccine
GB202013541D0 (en) Vaccine
GB202013534D0 (en) Vaccine
GB202013253D0 (en) Vaccine
GB202009402D0 (en) Vaccine
GB202005880D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)